Company news
Sophiris Bio Inc news in 2012
Sophiris Bio Inc's news releases, calls and decks from 2012, newest first.
Sophiris Bio Appoints a New Director to the Board
November 30, 2012
Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights
November 12, 2012
Sophiris Bio to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
November 6, 2012
Sophiris Bio Announces 12 Month Follow-Up Data from Phase 2b TRIUMPH Clinical Trial of PRX302 in Patients with Benign Prostatic Hyperplasia
October 9, 2012
Sophiris Bio to Present at the 11th Annual BIO Investor Forum
October 2, 2012
Sophiris Bio Announces Resignation of Alexander Casdin
September 14, 2012
Sophiris' Drug for Benign Prostatic Hyperplasia was Well Tolerated Using the Preferred Transrectal Route of Administration
August 31, 2012
Forty Year Industry Veteran Randall E. Woods Named CEO at Sophiris Bio
August 16, 2012
Sophiris Bio Reports Second Quarter Financial Results
August 13, 2012
Sophiris Bio Reports First Quarter Financial Results and Achievements
May 14, 2012
Protox Therapeutics Changes Name to Sophiris Bio
April 2, 2012